Roluperidone

Roluperidone (MIN-101, formerly MT-210 and CYR-101) is a cyclic amide (isoindolinone) derivative that combines high-affinity antagonism at the sigma-2 receptor (TMEM97; Ki 8.19 nM) and the serotonin 5-HT2A receptor (Ki 7.53 nM) with lower-affinity antagonism at alpha-1A adrenergic receptors (Ki 4.17 nM), while exhibiting essentially no binding at dopamine D1 through D5 receptors, muscarinic, cholinergic, or histaminergic receptors. This receptor binding profile distinguishes roluperidone from all marketed antipsychotics and underwrites a pharmacological rationale for addressing the negative symptoms of schizophrenia through nondopaminergic mechanisms. The sigma-2 receptor, identified in 2017 as the transmembrane protein TMEM97, is expressed at high density in cortical and hippocampal neurons and is implicated in calcium signaling, cholesterol homeostasis, autophagy, and the modulation of dopaminergic and glutamatergic neurotransmission. The 5-HT2A antagonist component promotes slow-wave sleep normalization, a deficit that is consistently documented in schizophrenia and that correlates with negative symptom severity. Roluperidone was originally synthesized by Mitsubishi Tanabe Pharma Corporation (designated MT-210), licensed through Cyrenaic Pharmaceuticals (CYR-101), and advanced through clinical development by Minerva Neurosciences (MIN-101). In a Phase 2b randomized, double-blind, placebo-controlled trial of 244 patients with stable schizophrenia and moderate-to-severe negative symptoms (MIN-101C03), roluperidone monotherapy at 32 mg and 64 mg produced statistically significant improvement on the PANSS negative symptom factor score at 12 weeks (effect sizes 0.45 and 0.58, respectively; both p < 0.025). In the subsequent Phase 3 trial (EMERGENT-3, NCT03397134, 513 patients), the 64 mg dose reached nominal statistical significance on the primary negative symptom endpoint in the modified intent-to-treat analysis (p = 0.044, effect size 0.26), with statistically significant improvements in social functioning on the Personal and Social Performance scale (p = 0.021, effect size 0.27) and a negative symptom responder rate of 39% versus 23% on placebo (p = 0.006). Network intervention analysis of both trials identified avolition as the directly targeted symptom, with improvements cascading across the broader negative symptom constellation. Pharmacokinetics are characterized by oral bioavailability of 73% to 81%, peak plasma concentration at approximately 3.5 hours, and a plasma elimination half-life of approximately 7 hours after a 64 mg dose, supporting once-daily administration. CYP2D6 is involved in metabolism, and poor or intermediate CYP2D6 metabolizers were excluded from the Phase 3 trial. Tolerability across both trials was notable for the absence of clinically meaningful weight gain, metabolic changes, extrapyramidal symptoms, or prolactin elevation; the principal safety signal was QTc interval prolongation leading to discontinuation of three patients at the 64 mg dose in the Phase 3 trial. Minerva Neurosciences filed a New Drug Application with the U.S. Food and Drug Administration in April 2023. The FDA issued a Complete Response Letter in February 2024, citing insufficient evidence of effectiveness from a single adequate trial, absence of data on concomitant antipsychotic administration, and the need for additional evidence of clinical meaningfulness. The compound remains in development as of the monograph date. This monograph documents the chemistry, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base, safety profile, and a comparative assessment of five compounds in the negative symptom treatment space against roluperidone on five competency standards. The compound is investigational and is not approved by any regulatory authority for any indication.